Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Rheumatology | Musculoskeletal | Orthopedics/Orthopedic Surgery
Clinical Trials: Ankylosing Spondylitis
A listing of clinical trials currently looking for volunteers to enroll in Ankylosing Spondylitis studies. Click on the closest city to find more detailed information on a research study in your area.
California
La Jolla : University of California, San Diego
OTIS Autoimmune Diseases in Pregnancy Project
Georgia
Alpharetta : CSI Research Inc
A Phase III, randomized, double-blind, placebo-controlled trial in patients with Ankylosing Spondylitis (AS).
Maryland
Wheaton : The Center for Rheumatology and Bone Research
A randomized double blind placebo controlled dose ranging study to evaluate the efficacy and safety of IL-6Ra mAb in patients with Ankylosing Spondylitis
Belgium
Aalst : Site Reference ID/Investigator# 4811
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Aalst : Site Reference ID/Investigator# 4821
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Aalst : Site Reference ID/Investigator# 4791
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Amel : Site Reference ID/Investigator# 28430
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Antwerp : Site Reference ID/Investigator# 4817
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
View More »
Antwerp : Site Reference ID/Investigator# 4830
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Arlon : Site Reference ID/Investigator# 4834
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Assebroek : Site Reference ID/Investigator# 4848
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Assebroek : Site Reference ID/Investigator# 4837
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ath : Site Reference ID/Investigator# 28454
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Audregnies : Site Reference ID/Investigator# 4773
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Baudour : Site Reference ID/Investigator# 4856
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Belsele : Site Reference ID/Investigator# 4810
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Bornem : Site Reference ID/Investigator# 28445
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Bruges : Site Reference ID/Investigator# 4842
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28448
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28449
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4766
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4770
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Ref # / Investigator 4815
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Ref # / Investigator 62674
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28439
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4863
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4797
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28420
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28405
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Erasme University Hospital
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Charleroi : Site Reference ID/Investigator# 28408
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Charleroi : Site Reference ID/Investigator# 28462
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Diepenbeek : Limburg University Centre
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Dinant : Site Reference ID/Investigator# 4772
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Edegem : Site Reference ID/Investigator# 4847
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Eeklo : Site Reference ID/Investigator# 28421
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Flemalle : Site Reference ID/Investigator# 4798
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Forchies-la-Marche : Site Reference ID/Investigator# 4831
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4855
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4803
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4781
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4792
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 28465
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4852
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 28452
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gent : Universitair Ziekenhuis, Afdeling Rheumatologie
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Gentbrugge : Site Reference ID/Investigator# 28424
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 28429
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4857
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4827
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4778
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4807
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4864
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4822
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gistel : Site Reference ID/Investigator# 4838
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gosselies : Site Reference ID/Investigator# 4799
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gosselies : Site Reference ID/Investigator# 4763
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Halle : Site Reference ID/Investigator# 28441
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hamme : Site Reference ID/Investigator# 4819
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hasselt : Site Reference ID/Investigator# 4775
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hasselt : Site Reference ID/Investigator# 4777
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hoboken : Site Reference ID/Investigator# 28428
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Keerbergen : Site Reference ID/Investigator# 4796
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Site Reference ID/Investigator# 4780
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Site Reference ID/Investigator# 28453
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Site Reference ID/Investigator# 28463
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
La Louviere : Site Reference ID/Investigator# 4768
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
La Louviere : Site Reference ID/Investigator# 4786
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
La Louviere : Site Reference ID/Investigator# 4764
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lennik : Site Reference ID/Investigator# 4805
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Leuven : Site Reference ID/Investigator# 4865
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Leuven : University Hospital Leuven
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Libramont-Chevigny : Site Reference ID/Investigator# 4849
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28425
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28407
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28419
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28451
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 4841
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lier : Site Reference ID/Investigator# 4782
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lobbes : Site Reference ID/Investigator# 4795
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lokeren : Site Reference ID/Investigator# 4779
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lommel : Site Reference ID/Investigator# 4808
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Malle : Site Reference ID/Investigator# 4839
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Marchienne-au-Pont : Site Reference ID/Investigator# 28436
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mechelen : Site Reference ID/Investigator# 4801
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mechelen : Site Reference ID/Investigator# 4844
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Merelbeke : Site Reference ID/Investigator# 4816
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Merksem : Site Reference ID/Investigator# 4806
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mons : Site Reference ID/Investigator# 4840
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mons : Site Reference ID/Investigator# 28440
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Montegnee : Site Reference ID/Investigator# 4820
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Montignies sur Sambre : Site Reference ID/Investigator# 4812
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Namur : Site Reference ID/Investigator# 4818
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Nazareth : Site Reference ID/Investigator# 4861
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Neupre Plainevaux : Site Reference ID/Investigator# 4765
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Nukerke : Site Reference ID/Investigator# 4789
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ostend : Site Reference ID/Investigator# 28432
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Plainevaux : Site Reference ID/Investigator# 4794
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Profondeville : Site Reference ID/Investigator# 4850
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Putte : Site Reference ID/Investigator# 28464
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Roeselare : Site Reference ID/Investigator# 28442
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Roeselare : Site Ref # / Investigator 28443
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Sijsele : Site Reference ID/Investigator# 46462
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Sijsele : Site Reference ID/Investigator# 4833
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Sint-Niklaas : Site Reference ID/Investigator# 4784
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Tielt : Site Reference ID/Investigator# 28446
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Turnhout : Site Reference ID/Investigator# 28447
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Veldegem : Site Reference ID/Investigator# 4774
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Verviers : Site Reference ID/Investigator# 28437
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Verviers : Site Reference ID/Investigator# 4851
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Waremme : Site Reference ID/Investigator# 28427
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Canada
Brampton : Site Ref # / Investigator 54758
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Brockville : Site Ref # / Investigator 65502
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Burlington : Site Ref # / Investigator 54764
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Burlington : Site Ref # / Investigator 67347
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Calgary : Site Ref # / Investigator 64274
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
View More »
Cranbrook : Site Ref # / Investigator 55242
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Fredericton : Site Ref # / Investigator 54748
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Fredericton : Site Ref # / Investigator 55256
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Hamilton : Site Ref # / Investigator 54762
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Hamilton : Site Ref # / Investigator 55417
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Hamilton : Site Ref # / Investigator 65011
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Kamloops : Site Ref # / Investigator 54577
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Laval : Site Ref # / Investigator 54576
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Mississauga : Site Ref # / Investigator 55401
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Mississauga : Site Ref # / Investigator 54581
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Mississauga : Site Ref # / Investigator 54750
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Montreal : Site Ref # / Investigator 63655
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Montreal : Site Ref # / Investigator 54754
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Montreal : Site Ref # / Investigator 54761
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Nepean : Site Ref # / Investigator 55410
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Ottawa : Site Ref # / Investigator 55296
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Outremont : Site Ref # / Investigator 54574
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Owen Sound : Site Ref # / Investigator 54583
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Prince George : Site Ref # / Investigator 55227
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Quebec City : Site Ref # / Investigator 45623
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Rimouski : Site Ref # / Investigator 54765
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
St. Catharines : Site Ref # / Investigator 67282
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
St. John's : Site Ref # / Investigator 54757
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
St-Leonard : Site Ref # / Investigator 55460
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Ref # / Investigator 54575
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Ref # / Investigator 55449
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Toronto : Site Ref # / Investigator 54751
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Trois-Rivieres : Site Ref # / Investigator 55469
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Vancouver : Site Ref # / Investigator 54572
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Victoria : Site Ref # / Investigator 55197
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
Winnipeg : Site Ref # / Investigator 54580
Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis
China
Baotou : The First Affiliated Hospital of Baotou Medical College
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Baotou city : Baotou Central Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Beijing : Shanghai Changning Guanghua Integrative Medicine Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Changsha : The Second Xiangya Hospital of Central South University
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Chengdu : Si Chuan Huaxi Hospital/Rheumatology Department
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
View More »
Chongqing : Daping Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Fuzhou : Fujian Provincial Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Guangzhou : The First Affiliated Hospital of Guangzhou University of Chinese Medicine
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Haerbin : No. 199
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Lanzhou : Lanzhou University Second Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Nanjing : Jiangsu Province Hospital/Department of Rheumatology
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Nantong : Affiliated Hospital of Nantong University
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Shanghai : Shanghai Jiaotong University Affiliated Third People's Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Taiyuan : The Second Hospital of Shanxi Medical University
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Urumqi : Xinjiang Uygur Autonomous Region People's Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Czech Republic
Brno : Site Ref # / Investigator 63774
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kromeriz : Site Ref # / Investigator 63775
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Ostrava : Site Ref # / Investigator 63769
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Pardubice : Site Ref # / Investigator 63772
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Estonia
Tallinn : Site Ref # / Investigator 71616
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Tallinn : Site Ref # / Investigator 71617
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Tartu : Site Ref # / Investigator 71618
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Finland
Helsinki : University Central Hospital, Division of Rheumatology
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
France
Paris : Universitat R. Descartes, Hopital Cochin
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Paris : Groupe Hopitalier Cochin
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Germany
Aachen : Site Reference ID/Investigator# 29862
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ahlen : Site Reference ID/Investigator# 30653
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ahrensburg : Site Reference ID/Investigator# 30676
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Aichhalden : Site Reference ID/Investigator# 28368
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Albstadt : Site Reference ID/Investigator# 30172
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
View More »
Altenburg : Site Reference ID/Investigator# 30677
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Altenholz : Site Reference ID/Investigator# 28401
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Amberg : Site Ref # / Investigator 66986
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Amberg : Site Reference ID/Investigator# 29981
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ammerbuch : Site Reference ID/Investigator# 29961
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Arnstadt : Site Reference ID/Investigator# 28402
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Augsburg : Site Reference ID/Investigator# 30666
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Abbach : Site Reference ID/Investigator# 30664
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Abbach : Site Reference ID/Investigator# 30673
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Bentheim : Site Reference ID/Investigator# 29809
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Bramstedt : Site Reference ID/Investigator# 30003
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Bramstedt : Site Reference ID/Investigator# 29982
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Endbach : Site Reference ID/Investigator# 30227
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Homburg : Site Reference ID/Investigator# 49718
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Iburg : Site Reference ID/Investigator# 30371
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Iburg : Site Reference ID/Investigator# 30421
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Kreuznach : Site Reference ID/Investigator# 30347
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Liebenwerda : Site Reference ID/Investigator# 30658
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Munder : Site Reference ID/Investigator# 30413
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Munster : Site Reference ID/Investigator# 49731
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Nauheim : Site Reference ID/Investigator# 29977
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Neuenahr : Site Reference ID/Investigator# 30271
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Neuenahr : Site Reference ID/Investigator# 28366
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Rappenau : Site Reference ID/Investigator# 29843
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Salzungen : Site Reference ID/Investigator# 59043
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Soden : Site Reference ID/Investigator# 29868
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Staffelstein : Site Reference ID/Investigator# 30333
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bad Sulze : Site Reference ID/Investigator# 30026
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Baden-Baden : Site Reference ID/Investigator# 30675
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bamberg : Site Reference ID/Investigator# 30323
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bautzen : Site Reference ID/Investigator# 28376
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bautzen : Site Reference ID/Investigator# 30329
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bayreuth : Site Reference ID/Investigator# 30423
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bayreuth : Site Reference ID/Investigator# 30442
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Charite Klinikum Steglitz
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Berlin : Charite Mitte
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Berlin : Charité University Medicine Berlin, Campus Benjamin-Franklin
Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
Berlin : Site Ref # / Investigator 71734
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30222
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30226
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30233
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 29938
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30461
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30660
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30311
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30393
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30776
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30463
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30395
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30287
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30289
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30245
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30784
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 49729
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Ref # / Investigator 66987
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 29841
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 30122
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Reference ID/Investigator# 29894
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Site Ref # / Investigator 59026
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Berlin : Pfizer Investigational Site
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
Berlin-Buch : Site Reference ID/Investigator# 30772
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bernau : Site Reference ID/Investigator# 30662
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Biberach : Site Reference ID/Investigator# 29931
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bietigheim-Bissingen : Site Reference ID/Investigator# 30435
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bietigheim-Bissingen : Site Reference ID/Investigator# 30434
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Blankenburg/Hart : Site Reference ID/Investigator# 29925
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Blaubeuren : Site Reference ID/Investigator# 28383
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bocholt : Site Reference ID/Investigator# 30341
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bogen : Site Reference ID/Investigator# 30305
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bonn : Site Reference ID/Investigator# 30280
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bonn : Site Reference ID/Investigator# 30182
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Bonn : Site Reference ID/Investigator# 30213
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Braunschweig : Site Reference ID/Investigator# 30263
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Braunschweig : Site Reference ID/Investigator# 29878
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Breitenbrunn : Site Reference ID/Investigator# 59023
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Celle : Site Reference ID/Investigator# 30152
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Chemnitz : Site Reference ID/Investigator# 30283
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Chemnitz : Site Reference ID/Investigator# 29806
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cologne : Site Reference ID/Investigator# 29971
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cologne : Site Reference ID/Investigator# 29941
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cologne : Site Reference ID/Investigator# 29808
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cologne : Site Reference ID/Investigator# 28388
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cologne : Site Reference ID/Investigator# 30207
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cottbus : Site Reference ID/Investigator# 28371
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Cottbus : Site Reference ID/Investigator# 30343
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Damp : Site Reference ID/Investigator# 30781
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Darmstadt : Site Ref # / Investigator 59029
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Darmstadt : Site Reference ID/Investigator# 30317
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Deggendorf : Site Reference ID/Investigator# 30381
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dortmund : Site Reference ID/Investigator# 30033
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dortmund : Site Reference ID/Investigator# 29930
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dortmund : Site Reference ID/Investigator# 30138
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dresden : Site Reference ID/Investigator# 29876
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dresden : Site Reference ID/Investigator# 28370
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dresden : Site Reference ID/Investigator# 30389
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dresden : Site Reference ID/Investigator# 30249
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dresden : Site Reference ID/Investigator# 30255
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dresden : Site Reference ID/Investigator# 30690
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Duisburg : Site Reference ID/Investigator# 30174
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Duisburg : Site Reference ID/Investigator# 28392
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dusseldorf : Site Reference ID/Investigator# 30212
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Dusseldorf : Site Reference ID/Investigator# 29893
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Eberswalde : Site Reference ID/Investigator# 30111
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Eisenberg : Site Reference ID/Investigator# 30205
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Elmshorn : Site Reference ID/Investigator# 30297
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Erfurt : Site Reference ID/Investigator# 30363
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Erfurt : Site Reference ID/Investigator# 30139
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Erfurt 99096 : Site Reference ID/Investigator# 30672
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Erlangen : Site Reference ID/Investigator# 29844
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Essen : Site Reference ID/Investigator# 30694
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Essen : Site Reference ID/Investigator# 29923
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Frankenberg : Site Reference ID/Investigator# 30251
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Frankfurt : Site Reference ID/Investigator# 30259
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Frankfurt : Site Reference ID/Investigator# 28385
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Frankfurt : Site Reference ID/Investigator# 30035
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Fraureuth : Site Reference ID/Investigator# 30359
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Freiberg : Site Reference ID/Investigator# 30365
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Freiburg : Site Reference ID/Investigator# 28377
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Freising : Site Reference ID/Investigator# 29896
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Friedberg : Site Reference ID/Investigator# 29945
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Friedrichroda : Site Reference ID/Investigator# 29997
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Geilenkirchen : Site Reference ID/Investigator# 29835
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Gera : Site Reference ID/Investigator# 30093
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
GieBen : Site Reference ID/Investigator# 29884
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Goslar : Site Reference ID/Investigator# 30325
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Grafelfing : Site Reference ID/Investigator# 30367
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Greifswald : Site Reference ID/Investigator# 29911
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Greifswald : Site Reference ID/Investigator# 30327
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Greifswald : Site Reference ID/Investigator# 30214
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Guestrow : Site Ref # / Investigator 66985
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Halle : Site Ref # / Investigator 59027
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Halle : Site Reference ID/Investigator# 30681
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Halle : Site Reference ID/Investigator# 29934
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Halle : Site Reference ID/Investigator# 30663
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Halle : Site Reference ID/Investigator# 30680
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Halle : Site Reference ID/Investigator# 30774
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30692
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30444
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30425
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30432
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30433
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30339
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30391
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30405
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 28384
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 28369
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Ref # / Investigator 66984
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30671
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30431
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30345
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30291
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30691
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30693
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 29872
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 29898
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 30010
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 28374
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 28399
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hamburg : Site Reference ID/Investigator# 28403
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hannover : Site Reference ID/Investigator# 30685
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hanover : Site Ref # / Investigator 66983
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hanover : Site Ref # / Investigator 59025
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hanover : Site Reference ID/Investigator# 29897
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hanover : Site Reference ID/Investigator# 30299
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hanover : Site Reference ID/Investigator# 30261
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Harrislee : Site Reference ID/Investigator# 29867
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heide : Site Reference ID/Investigator# 30042
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heidelberg : Site Reference ID/Investigator# 30294
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heidelberg : Site Reference ID/Investigator# 30307
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heidelberg : Site Reference ID/Investigator# 30253
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heidelberg : Site Reference ID/Investigator# 30293
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heidelberg : Site Reference ID/Investigator# 30656
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Heilbad Heiligenstadt : Site Reference ID/Investigator# 30150
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Herne : Rheumazentrum Ruhrgebiet
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Herne : Rheumazentrum Ruhrgebiet
Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
Herrsching : Site Reference ID/Investigator# 30688
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hettstedt : Site Reference ID/Investigator# 29984
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hildesheim : Site Reference ID/Investigator# 29805
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hof : Site Reference ID/Investigator# 30148
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hofheim : Site Reference ID/Investigator# 29879
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hohenfelde : Site Reference ID/Investigator# 30231
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hoyerswerda : Site Reference ID/Investigator# 30132
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Illertissen : Site Reference ID/Investigator# 29956
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Immenstadt : Site Reference ID/Investigator# 29846
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Jena : Site Reference ID/Investigator# 49721
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Julich : Site Reference ID/Investigator# 29999
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kahla : Site Reference ID/Investigator# 30428
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kahla : Site Reference ID/Investigator# 30427
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kaiserslautern : Site Reference ID/Investigator# 30361
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kaiserslautern : Site Ref # / Investigator 71733
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Karlstadt : Site Ref # / Investigator 59030
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kassel : Site Reference ID/Investigator# 30016
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Konigs Wusterhausen : Site Reference ID/Investigator# 30411
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Konstanz : Site Reference ID/Investigator# 29939
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kressbronn : Site Reference ID/Investigator# 29858
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kronach : Site Reference ID/Investigator# 30185
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Kyritz : Site Reference ID/Investigator# 29985
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Lahr : Site Reference ID/Investigator# 29871
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Landau : Site Reference ID/Investigator# 30239
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leipzig : Site Reference ID/Investigator# 30355
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leipzig : Site Reference ID/Investigator# 29836
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leipzig : Site Reference ID/Investigator# 30158
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leipzig : Site Reference ID/Investigator# 30281
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leipzig : Site Reference ID/Investigator# 30668
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leipzig : Site Reference ID/Investigator# 49712
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Leverkusen : Site Reference ID/Investigator# 30652
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Lichtenfels : Site Reference ID/Investigator# 29889
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Lichtenstein : Site Reference ID/Investigator# 30331
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Lippstadt : Site Reference ID/Investigator# 29926
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Lubeck : Site Reference ID/Investigator# 29891
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ludwigsfelde 14974 : Site Reference ID/Investigator# 30319
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ludwigslust : Site Reference ID/Investigator# 30241
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Luebeck : Site Reference ID/Investigator# 30021
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Luneburg : Site Reference ID/Investigator# 30679
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Magdeburg : Site Reference ID/Investigator# 28372
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Magdeburg : Site Reference ID/Investigator# 29851
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Mainz : Site Ref # / Investigator 59028
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Marktredwitz : Site Reference ID/Investigator# 30230
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Marl : Site Reference ID/Investigator# 28398
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Menz : Site Reference ID/Investigator# 30265
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Minden : Site Reference ID/Investigator# 29963
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Mittelherwigsdorf : Site Reference ID/Investigator# 30237
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Monchengladbach : Site Reference ID/Investigator# 29895
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Monchengladbach : Site Reference ID/Investigator# 30429
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Monchengladbach : Site Reference ID/Investigator# 30430
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Monkeberg : Site Reference ID/Investigator# 28389
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Muenster : Site Reference ID/Investigator# 30215
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Muhlhausen : Site Reference ID/Investigator# 30209
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Mulheim : Site Reference ID/Investigator# 30157
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Mullheim : Site Reference ID/Investigator# 29854
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munchen : Site Reference ID/Investigator# 30194
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munchen : Site Reference ID/Investigator# 30176
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munchen : Site Reference ID/Investigator# 30309
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
München : Ludwigs-Maximilian-Universität
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Munich : Site Ref # / Investigator 30674
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munich : Site Reference ID/Investigator# 28394
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munich : Site Ref # / Investigator 71739
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munich : Site Reference ID/Investigator# 30775
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Munster : Site Reference ID/Investigator# 30661
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Naumburg : Site Reference ID/Investigator# 30659
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Naunhof : Site Reference ID/Investigator# 28391
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neubrandenburg : Site Reference ID/Investigator# 29811
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neubrandenburg : Site Reference ID/Investigator# 29847
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neuburg : Site Reference ID/Investigator# 30669
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neumunster : Site Reference ID/Investigator# 29887
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neunkirchen : Site Reference ID/Investigator# 49714
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neuss : Site Ref # / Investigator 66982
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Neustadt : Site Reference ID/Investigator# 30682
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Niederbrombach : Site Reference ID/Investigator# 29976
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Niefern-Oschelbronn : Site Reference ID/Investigator# 30438
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Nienburg : Site Reference ID/Investigator# 30436
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Nienburg : Site Reference ID/Investigator# 30437
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Nuernberg : Site Reference ID/Investigator# 49719
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Nurnberg : Site Reference ID/Investigator# 30657
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Offenburg : Site Reference ID/Investigator# 28363
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Oldenburg : Site Reference ID/Investigator# 30267
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Osnabruck : Site Reference ID/Investigator# 29859
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Paderborn : Site Reference ID/Investigator# 30149
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Parchim : Site Reference ID/Investigator# 30401
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Parsberg : Site Reference ID/Investigator# 29965
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Passau : Site Reference ID/Investigator# 30667
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Petershagen : Site Reference ID/Investigator# 30228
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Pfaffenhofen 85276 : Site Reference ID/Investigator# 30335
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Pfullendorf : Site Reference ID/Investigator# 30686
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Pirna : Site Reference ID/Investigator# 30654
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Plauen : Site Reference ID/Investigator# 29853
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Plauen : Site Reference ID/Investigator# 28381
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Potsdam : Site Reference ID/Investigator# 28400
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Potsdam : Site Reference ID/Investigator# 30440
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Potsdam : Site Ref # / Investigator 71735
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Prum : Site Reference ID/Investigator# 30351
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Puttlingen : Site Reference ID/Investigator# 29986
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Radebeul : Site Reference ID/Investigator# 30407
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Radebeul : Site Reference ID/Investigator# 30337
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ratingen : Site Reference ID/Investigator# 29804
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ratzeburg : Site Reference ID/Investigator# 30415
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Regensburg : Site Ref # / Investigator 30687
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Regensburg : Site Reference ID/Investigator# 30295
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Regensburg : Site Reference ID/Investigator# 30303
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Reken : Site Reference ID/Investigator# 30689
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rendsburg : Site Reference ID/Investigator# 30315
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rheda-Wiedenbrueck : Site Reference ID/Investigator# 49715
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rheine : Site Reference ID/Investigator# 30670
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rickenbach : Site Reference ID/Investigator# 29964
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Riesa : Site Reference ID/Investigator# 30321
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rinteln : Site Reference ID/Investigator# 30036
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rostock : Site Reference ID/Investigator# 30446
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rostock : Site Reference ID/Investigator# 30357
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rothenburg : Site Reference ID/Investigator# 30379
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Rudersdorf : Site Reference ID/Investigator# 29958
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Saarbruecken : Site Reference ID/Investigator# 28393
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Salzwedel : Site Reference ID/Investigator# 30695
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Sande : Site Reference ID/Investigator# 30091
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schramberg : Site Reference ID/Investigator# 30313
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schutterwald : Site Reference ID/Investigator# 29913
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schwandorf : Site Reference ID/Investigator# 30171
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schwerin : Site Reference ID/Investigator# 29881
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schwerin : Site Reference ID/Investigator# 30243
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schwerin : Site Reference ID/Investigator# 30275
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Schwerte : Site Reference ID/Investigator# 29957
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Seesen : Site Reference ID/Investigator# 30235
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Senden : Site Reference ID/Investigator# 29849
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Singen : Site Ref # / Investigator 66988
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Sinsheim : Site Reference ID/Investigator# 30387
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Soltau : Site Reference ID/Investigator# 30417
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Stadtbergen : Site Reference ID/Investigator# 30349
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Stadthagen : Site Reference ID/Investigator# 29946
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Stuttgart : Site Reference ID/Investigator# 29857
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Stuttgart : Site Reference ID/Investigator# 30136
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Stuttgart : Site Reference ID/Investigator# 30020
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Stuttgart : Site Reference ID/Investigator# 30778
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Suhl : Site Reference ID/Investigator# 29905
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Torgelow : Site Reference ID/Investigator# 30383
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Treuenbrietzen : Site Reference ID/Investigator# 49724
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Treuenbrietzen : Site Reference ID/Investigator# 30697
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Tubingen : Site Reference ID/Investigator# 29962
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Tuebingen : Site Reference ID/Investigator# 30031
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ulm : Site Reference ID/Investigator# 30369
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Ulm : Site Ref # / Investigator 30137
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Viersen : Site Reference ID/Investigator# 29818
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Villingen-Schwenningen : Site Reference ID/Investigator# 30273
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Waltrop : Site Reference ID/Investigator# 30683
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Weener : Site Reference ID/Investigator# 30377
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Weiden : Site Reference ID/Investigator# 49720
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wiesbaden : Site Reference ID/Investigator# 30277
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wiesbaden : Site Reference ID/Investigator# 30419
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wiesbaden : Site Reference ID/Investigator# 30224
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wilhelmshaven : Site Reference ID/Investigator# 30465
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wismar : Site Reference ID/Investigator# 30154
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wittlich : Site Reference ID/Investigator# 49726
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wuerzburg : Site Reference ID/Investigator# 30773
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Wuppertal : Site Reference ID/Investigator# 29940
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Zerbst : Site Reference ID/Investigator# 30467
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Zeven : Site Reference ID/Investigator# 30779
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Zwickau : Site Reference ID/Investigator# 30301
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Zwiesel : Site Reference ID/Investigator# 28365
Safety and Effectiveness of Adalimumab (Humira) in Patients With Ankylosing Spondylitis in Clinical Routine
Hungary
Budapest : Site Ref # / Investigator 65210
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Budapest : Site Ref # / Investigator 65206
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Budapest : Site Ref # / Investigator 49883
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Debrecen : Site Ref # / Investigator 65208
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Debrecen : Site Ref # / Investigator 65224
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
View More »
Eger : Site Ref # / Investigator 65205
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Esztergom : Site Ref # / Investigator 65222
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Gyor : Site Ref # / Investigator 65207
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Gyula : Site Ref # / Investigator 65223
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Heviz : Site Ref # / Investigator 65225
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kecskemet : Site Ref # / Investigator 65203
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kistarcsa : Site Ref # / Investigator 65209
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Miskolc : Site Ref # / Investigator 65214
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Nyiregyhaza : Site Ref # / Investigator 65211
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Pecs : Site Ref # / Investigator 65221
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Szeged : Site Ref # / Investigator 65204
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Szekesfehervar : Site Ref # / Investigator 65227
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Szombathely : Site Ref # / Investigator 65213
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Veszprem : Site Ref # / Investigator 65202
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Japan
Aichi : Site Ref # / Investigator 59605
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Aichi : Site Ref # / Investigator 64970
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Aichi : Site Ref # / Investigator 68725
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Aichi : Site Ref # / Investigator 59603
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Akita : Site Ref # / Investigator 54989
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
View More »
Aomori : Site Ref # / Investigator 51171
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Ref # / Investigator 54713
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Ref # / Investigator 54720
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Ref # / Investigator 51095
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chiba : Site Ref # / Investigator 51096
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Chuo : Site Ref # / Investigator 54991
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fuchu : Site Ref # / Investigator 54996
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fujieda : Site Ref # / Investigator 79755
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 55016
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 80934
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51168
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51163
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51165
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51166
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51114
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51124
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukuoka : Site Ref # / Investigator 51164
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Fukushima : Site Ref # / Investigator 51086
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gifu : Site Ref # / Investigator 51183
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gifu : Site Ref # / Investigator 54709
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gifu : Site Ref # / Investigator 59585
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Gyoda : Site Ref # / Investigator 79756
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hamamatsu : Site Ref # / Investigator 54816
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hannan : Site Ref # / Investigator 79773
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hirakata : Site Ref # / Investigator 51189
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hirosaki : Site Ref # / Investigator 51147
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 51126
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 51127
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 51155
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 54983
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 51162
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 55015
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hiroshima : Site Ref # / Investigator 79754
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hokkaido : Site Ref # / Investigator 54715
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hokkaido : Site Ref # / Investigator 51122
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hokkaido : Site Ref # / Investigator 51083
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hokkaido : Site Ref # / Investigator 54987
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hyogo : Site Ref # / Investigator 54822
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hyogo : Site Ref # / Investigator 51195
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Hyogo : Site Ref # / Investigator 64968
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ichinoseki : Site Ref # / Investigator 79758
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ikoma : Site Ref # / Investigator 64934
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Isahaya : Site Ref # / Investigator 59607
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Iwafune : Site Ref # / Investigator 51088
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izumo : Site Ref # / Investigator 51160
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izunokuni : Site Ref # / Investigator 51190
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Izunokuni : Site Ref # / Investigator 51187
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Joetsu : Site Ref # / Investigator 84019
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Joetsu : Site Ref # / Investigator 84018
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kaga : Site Ref # / Investigator 79759
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kagoshima : Site Ref # / Investigator 55020
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kagoshima : Site Ref # / Investigator 67172
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kagoshima : Site Ref # / Investigator 55021
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanagawa : Site Ref # / Investigator 54998
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanagawa : Site Ref # / Investigator 54999
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanagawa : Site Ref # / Investigator 54712
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Ref # / Investigator 55009
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Ref # / Investigator 55008
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Ref # / Investigator 64936
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kanazawa : Site Ref # / Investigator 64948
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kashihara : Site Ref # / Investigator 67171
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kashihara : Site Ref # / Investigator 71474
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kasugai : Site Ref # / Investigator 75096
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kasugai : Site Ref # / Investigator 75099
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawagoe : Site Ref # / Investigator 51117
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawagoe : Site Ref # / Investigator 51152
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawasaki : Site Ref # / Investigator 75095
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kawasaki : Site Ref # / Investigator 51188
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kitakyushu : Site Ref # / Investigator 51167
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kitakyushu : Site Ref # / Investigator 59588
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Ref # / Investigator 54725
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Ref # / Investigator 54982
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Ref # / Investigator 54724
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kobe : Site Ref # / Investigator 59601
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kudamatsu : Site Ref # / Investigator 51158
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kumamoto : Site Ref # / Investigator 59586
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kurashiki : Site Ref # / Investigator 51170
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kurume : Site Ref # / Investigator 55017
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 55010
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 55011
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 51119
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 51198
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 51161
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 51118
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 51156
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 51157
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 64994
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Kyoto : Site Ref # / Investigator 64933
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maebashi : Site Ref # / Investigator 54990
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maebashi : Site Ref # / Investigator 51087
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maebashi : Site Ref # / Investigator 84017
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Maizuru : Site Ref # / Investigator 79753
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Matsuyama : Site Ref # / Investigator 49884
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Minato : Site Ref # / Investigator 51151
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Minato : Site Ref # / Investigator 51154
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Miyazaki : Site Ref # / Investigator 67173
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagakute : Site Ref # / Investigator 59591
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagakute : Site Ref # / Investigator 51169
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagakute : Site Ref # / Investigator 64967
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagano : Site Ref # / Investigator 59608
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagano : Site Ref # / Investigator 51153
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagano : Site Ref # / Investigator 54992
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagaokakyo : Site Ref # / Investigator 64931
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagasaki : Site Ref # / Investigator 51123
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # / Investigator 54819
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # /Investigator 59584
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # / Investigator 75097
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # / Investigator 59600
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # / Investigator 54985
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # / Investigator 54821
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nagoya : Site Ref # / Investigator 51182
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nara : Site Ref # / Investigator 51186
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nara : Site Ref # / Investigator 54726
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Niigata : Site Ref # / Investigator 54814
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nirasaki : Site Ref # / Investigator 84020
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nishinomiya : Site Ref # / Investigator 55004
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Nisshin : Site Ref # / Investigator 84194
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Obihiro : Site Ref # / Investigator 59604
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Obihiro : Site Ref # / Investigator 75094
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Oita : Site Ref # / Investigator 59598
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Oita : Site Ref # / Investigator 55019
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Okayama : Site Ref # / Investigator 59606
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Okayama : Site Ref # / Investigator 55013
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Okayama : Site Ref # / Investigator 54723
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Ono : Site Ref # / Investigator 84022
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 55001
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 55002
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 64935
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 59590
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 54984
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51192
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51149
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51194
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51173
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 64932
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 59602
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 54820
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 54716
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51185
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51191
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51196
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51197
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51125
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51113
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Osaka : Site Ref # / Investigator 51150
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Otsu : Site Ref # / Investigator 64938
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Otsu : Site Ref # / Investigator 55012
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saga : Site Ref # / Investigator 55018
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sagamihara : Site Ref # / Investigator 54818
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saitama : Site Ref # / Investigator 54986
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saitama : Site Ref # / Investigator 51120
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saitama : Site Ref # / Investigator 54997
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Saitama : Site Ref # / Investigator 51097
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sakai : Site Ref # / Investigator 84021
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Ref # / Investigator 59597
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Ref # / Investigator 51084
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Ref # / Investigator 51085
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sapporo : Site Ref # / Investigator 54988
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sendai : Site Ref # / Investigator 51116
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Sendai : Site Ref # / Investigator 51148
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Shimane : Site Ref # / Investigator 59593
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Shinjuku-ku : Site Ref # / Investigator 54994
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Takamatsu : Site Ref # / Investigator 54710
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Takatsuki : Site Ref # / Investigator 51193
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Takatsuki : Site Ref # / Investigator 55003
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tochigi : Site Ref # / Investigator 59592
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 59587
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 79757
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 71476
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 68726
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51172
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54711
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54995
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54718
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54815
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51121
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51115
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51089
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51093
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51082
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 64937
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54993
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54717
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54721
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 54722
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51174
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51090
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51091
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51092
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51094
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51129
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tokyo : Site Ref # / Investigator 51146
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tomakomai : Site Ref # / Investigator 59596
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 64996
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 55005
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 55006
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 55007
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 51128
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 59599
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyama : Site Ref # / Investigator 59589
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyoake : Site Ref # / Investigator 64995
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Toyohashi : Site Ref # / Investigator 80918
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tsukuba : Site Ref # / Investigator 59594
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Tsuyama : Site Ref # / Investigator 71475
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Urayasu : Site Ref # / Investigator 54714
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Wakayama : Site Ref # / Investigator 54817
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yamaguchi : Site Ref # / Investigator 54823
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yamaguchi : Site Ref # / Investigator 51159
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yamaguchi : Site Ref # / Investigator 64969
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Ref # / Investigator 75098
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Ref # / Investigator 55000
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Ref # / Investigator 80933
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yokohama : Site Ref # / Investigator 59595
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Yonago : Site Ref # / Investigator 55014
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
Korea, Republic of
Seoul : Hanyang University Hospital for rheumatic disease
The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection
Netherlands
Amsterdam : Academic Ziekenhuis
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Haarlem : Merck Sharp & Dohme B.V.
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
Maastricht : University Hospital Maastricht
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Norway
Lillehammer : Lillehammer Hospital for Rheumatic Diseases
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
Romania
Brasov : Site Ref # / Investigator 66393
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Brasov : Site Ref # / Investigator 66394
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Ref # / Investigator 69661
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Ref # / Investigator 66377
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Ref # / Investigator 66378
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
View More »
Bucharest : Site Ref # / Investigator 66364
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Bucharest : Site Ref # / Investigator 66366
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Contanta : Site Ref # / Investigator 66398
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Ref # / Investigator 69390
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Ref # / Investigator 66389
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Craiova : Site Ref # / Investigator 66390
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Deva : Site Ref # / Investigator 66402
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Deva : Site Ref # / Investigator 66403
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Iasi : Site Ref # / Investigator 66384
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Iasi : Site Ref # / Investigator 66387
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Sibiu : Site Ref # / Investigator 66397
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Sibiu : Site Ref # / Investigator 66400
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Targu-Mures : Site Ref # / Investigator 66391
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Timisoara : Site Ref # / Investigator 66383
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Slovakia
Banska Bystrica : Site Ref # / Investigator 64342
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Kosice : Site Ref # / Investigator 64343
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Piestany : Site Ref # / Investigator 65732
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
Ukraine
Kharkov : Site Ref # / Investigator 70696
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
United Kingdom
Cambridge : University of Cambridge/ Clin Med
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Leeds : University of Leeds
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
London : Novartis Investigative Site
Efficacy at 16 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Ankylosing Spondylitis (AS)
